Keith Wirth

Dr. Keith Wirth

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2023 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
DCDongmei Chen
Dongmei Chen
KWKeith Wirth
Keith Wirth
SKScott Kizy
Scott Kizy
JMJoseph M. Muretta
Joseph M. Muretta
TMTodd W. Markowski
Todd W. Markowski
DBDavid Bernlohr
David Bernlohr
Fatty acid binding protein 4 (FABP4) is a secreted adipokine linked to obesity and progression of a variety of cancers. Obesity increases extracellular FABP4 (eFABP4) levels in animal models and in obese breast cancer patients compared with lean healthy controls. Using MCF-7 and T47D breast cancer epithelial cells, we show herein that eFABP4 stimulates cellular proliferation in a time and concentration dependent manner while the non-fatty acid-binding mutant, R126Q, failed to potentiate growth. When E0771 murine breast cancer cells were injected into mice, FABP4 null animals exhibited delayed tumor growth and enhanced survival compared with injections into control C57Bl/6J animals. eFABP4 treatment of MCF-7 cells resulted in a significant increase in phosphorylation of extracellular signal-regulated kinase 1/2 (pERK), transcriptional activation of nuclear factor E2-related factor 2 (NRF2) and corresponding gene targets ALDH1A1, CYP1A1, HMOX1, SOD1 and decreased oxidative stress, while R126Q treatment did not show any effects. Proximity-labeling employing an APEX2–FABP4 fusion protein revealed several proteins functioning in desmosomes as eFABP4 receptor candidates including desmoglein (DSG), desmocollin, junction plankoglobin, desomoplankin, and cytokeratins. AlphaFold modeling predicted an interaction between eFABP4, and the extracellular cadherin repeats of DSG2 and pull-down and immunoprecipitation assays confirmed complex formation that was potentiated by oleic acid. Silencing of DSG2 in MCF-7 cells attenuated eFABP4 effects on cellular proliferation, pERK levels, and ALDH1A1 expression compared with controls. Implications: These results suggest desmosomal proteins, and in particular desmoglein 2, may function as receptors of eFABP4 and provide new insight into the development and progression of obesity-associated cancers.

1 April 2015 in The American Journal of Surgery
Verified
Journal Article
Closed access
KWKeith Wirth
Keith Wirth
BMBethany Malone
Bethany Malone
CTChristopher Turner
Christopher Turner
RSRobert Schulze
Robert Schulze
WWWarren Widmann
Warren Widmann
ASAliu Sanni
Aliu Sanni

1 February 2014 in The American Journal of Surgery
Verified
Journal Article
Closed access
KWKeith Wirth
Keith Wirth
BMBethany Malone
Bethany Malone
KBKaylene Barrera
Kaylene Barrera
WWWarren D. Widmann
Warren D. Widmann
CTChristopher Turner
Christopher Turner
ASAliu Sanni
Aliu Sanni

14 October 2020 in Obesity Science & Practice
Verified
Journal Article
Open access
PDF file
KWKeith Wirth
Keith Wirth
SKScott Kizy
Scott Kizy
HAHisham Abdelwahab
Hisham Abdelwahab
JZJianying Zhang
Jianying Zhang
SASantosh Agarwal
Santosh Agarwal
DLDaniel B. Leslie
Daniel B. Leslie
Background: The Medicare population is increasing while the prevalence of obesity remains high. Bariatric surgery is the most efficacious treatment of obesity and its comorbidities. The objective of this investigation was to assess trends in utilization, readmission, mortality, and cost of bariatric surgery in the Medicare population.Methods: Utilizing the Medicare Provider Analysis and Review database, patients with clinically severe obesity undergoing laparoscopic Roux‐en‐Y gastric bypass (RYGB), laparoscopic sleeve gastrectomy (SG), and laparoscopic adjustable gastric banding (LAGB) from 2011–2015 were identified. Trends in procedure selection, readmissions, mortality, and cost were examined. A multivariable logistic regression analysis to evaluate factors associated with readmission and mortality was performed.Results: Of the 73,718 patients identified, 53,949 (73%) of patients were enrolled in Medicare due to disability, 19,191 (26%) due to age, and 578 (<1%) due to end stage renal disease (ESRD). Utilization of SG increased (1% in 2011 to 61% in 2015), while utilization of RYGB (68% to 32%) and LAGB (31% to 1%) decreased. Length of stay (LOS) was highest after RYGB (2.54 days), and lowest after LAGB (1.32 days). LOS decreased from 2.23 days in 2011 to 2.12 days in 2015. Thirty‐day readmissions were 8.24% for the disabled, 5.5% for the elderly, 12.8% with ESRD. Odds of readmission increased with black race, higher body mass index (BMI), and RYGB. Readmission decreased from 8% in 2011 to 7% in 2015. Thirty‐day mortality was 0.22% in the disabled, and 0.28% in the elderly. Odds of 30‐day mortality increased among men, those with higher BMI, some comorbidities, and those who underwent RYGB. Cost of SG decreased while cost of RYGB increased.Conclusions: Among the Medicare population, an increase in SG while a decrease in RYGB and LAGB utilization was noted from 2011–2015. Readmissions and cost have decreased, while mortality has remained low.

16 September 2024
Verified
Other
Open access
PDF file
DCDongmei Chen
Dongmei Chen
KWKeith Wirth
Keith Wirth
SKScott Kizy
Scott Kizy
JMJoseph M. Muretta
Joseph M. Muretta
TMTodd W. Markowski
Todd W. Markowski
DBDavid Bernlohr
David Bernlohr
S2. Predicted orientation of the F57 side chain in the apoFABP4 form.

16 September 2024
Verified
Other
Open access
PDF file
DCDongmei Chen
Dongmei Chen
KWKeith Wirth
Keith Wirth
SKScott Kizy
Scott Kizy
JMJoseph M. Muretta
Joseph M. Muretta
TMTodd W. Markowski
Todd W. Markowski
DBDavid Bernlohr
David Bernlohr
S2. Predicted orientation of the F57 side chain in the apoFABP4 form.